OncoMed Presents Positive Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at SITC Conference

OncoMed Pharmaceuticals Inc. OMED presented new preclinical data for anti-DLL4 combined with anti-VEGF and anti-PD1 during the Society for Immunotherapy of Cancer (SITC) Conference.   A series of preclinical experiments compared the impact of anti-DLL4/VEGF bispecific and a triple blockade of DLL4-VEGF-PD1 on anti-tumor immune responses.  The combination of anti-DLL4/VEGF and anti-PD1 was found to have more potent anti-tumor and enhanced immuno-oncology activity than either agent alone across a number of measures.  The triple blockade of DLL4-VEGF-PD1 significantly inhibited tumor growth with more pronounced tumor regression.  The addition of anti-DLL4/VEGF also improved anti-tumor activity of anti-PD1 alone in both PD1 responsive and non-responsive cancers in murine models.  "These data highlight the ability of the anti-DLL4/VEGF bispecific to combine with anti-PD1 and to modulate anti-tumor immune responses," said Austin Gurney, PhD, Senior Vice President of Molecular and Cellular Biology.  "In addition to increased anti-tumor efficacy, we note enhanced generation of memory T cell responses and reduced tumor-associated macrophages.  These results show that co-targeting of DLL4 and VEGF with PD1 might be an See full press release